

## At a glance

In Europe, prostate cancer (PC) is the second most frequent type of cancer in men and the third most lethal. Current clinical practices often lead to overdiagnosis and overtreatment, necessitating more effective tools for optimal management of the disease.

The EU-funded ProCancer-I project proposes to develop advanced artificial intelligence models to address unmet clinical needs: diagnosis, metastases detection and prediction of response to treatment.

ProCancer-I has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 952159  
<http://ec.europa.eu/digital-single-market/ehealth>

## CONSORTIUM



## MORE ABOUT THE PROJECT

-  @ProCancer.I
-  @ProCancer\_I
-  @procancer-i-project
-  [www.procancer-i.eu](http://www.procancer-i.eu)

# ProCancer-I


**An AI Platform  
integrating imaging data  
and models, supporting  
precision care through  
prostate cancer's  
continuum**



European  
Commission

Horizon 2020  
European Union funding  
for Research & Innovation

## Use cases mapped along the prostate cancer management continuum



### Project ID

The ProCancer - I Project brings together 20 world-renowned partners in prostate cancer imaging, world leaders in Artificial Intelligence and innovative SMEs. Their key objective is to design and deliver an AI Platform, integrating imaging data and models, in order to accelerate the progress in PCa precision care through prostate cancer's continuum.

### Challenges

#### Clinical

Identify prostate cancer with high accuracy, as early as possible, to stratify patients according to disease aggressiveness and to tailor therapy (or non-therapy) based on the risk of progression, comorbidities and life expectancy

#### Technical

Create a unique dataset in terms of data quantity, quality and diversity to be used for model development and validation

### Impact

The goal is to address crucial clinical questions related to prostate cancer management through the disease continuum and to deliver a novel cloud based infrastructure enabling improved diagnosis, treatment and follow-up with the use of AI based solutions that contribute to more precise and personalised management of prostate cancer.